Advertisement
Journal of Oncology Practice  
Search for:
Limit by:
  Browse by Topic or Issue
Home Search or Browse JOP Subscriptions PDA Services E-mail Alerts Customer Service

Journal of Oncology Practice, Vol 3, No 4 (July), 2007: pp. 196
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JOP.0742502

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

Practical Tips

FAQs From the Coding and Reimbursement Hotline: Port Flush, 59 and 25 Modifiers, Anticoagulation, and Management

ASCO's Coding and Reimbursement Hotline receives calls that relate to a wide variety of issues and topics. Some recent questions that have been answered by the hotline are provided below.

Can we charge an office visit such as 99213 and also 96523 for the flush procedure?

No. Medicare will not pay separately for a port flush code (96523) when it is performed on the same day as any other physician fee schedule service. The port flush code, however, is separately payable if it is the only service billed that day. There are National Correct Coding Initiative edits in place that reinforce this policy. Therefore, you have the option to bill either the office visit or the port flush code with Medicare.The Current Procedural Terminology (CPT) manual clearly states that the 96523 code should not be billed if an injection or infusion is provided on the same day. Therefore, private payers may have put in place specific coverage policies or billing edits similar to Medicare. It is best to verify the coverage policy for this service with your individual payers.

What is the rationale for appending the -59 modifier to the hydration services when reporting them with chemotherapy administration services?

Hydration services performed during chemotherapy are not separately payable under the Medicare program. The -59 modifier is used on the hydration administration codes to attest that the hydration was done either before or after the chemotherapy administration.Private payers may have varying policies on hydration services performed with chemotherapy. As always, you should verify those policies with each individual payer.

When can we use 99212 through 99215 with a -25 modifier on days intravenous chemotherapy is given?

Medicare will pay for both a drug administration service and a visit on the same day if a level 2 through 5 visit is performed. The visit code must be accompanied by modifier -25 to indicate that a separately identifiable evaluation and management service was furnished in addition to the drug administration.The language found in the CPT manual specifically states that a different diagnosis is not required for evaluation and management services provided on the same day as drug administration services. As a reminder, the documentation should always support the level of service billed.

CPT includes codes for anticoagulation management. Does Medicare pay for these codes?

Two new codes for anticoagulation management (CPT codes 99363 and 99364) were published in the 2007 CPT manual. While private payers may recognize these codes, Medicare does not. The 2007 Medicare Physician Fee Schedule shows 99363 and 99364 as bundled services that are not separately billable.

Is there a way to know if my state has specific laws relating to the coverage of off-label indications used in cancer treatment?

Yes. One of the best resources to determine whether or not your state has laws relating to the coverage of off-label indications can be found on the National Cancer Institute's (NCI; Bethesda, Maryland) Web site. NCI follows state legislation, proposed and enacted, that addresses off-label indications used in cancer treatment. The organization has put together a chart containing the states and the relevant information on off-label coverage. The link to the chart is http://www.scld-nci.net/Data/off-label_use_06_30_05.pdf.

Staff at ASCO are available to answer questions from oncologists and their practice staff. Give us a call at 703-299-1054 or e-mail us at practice{at}asco.org.





This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

About
JOP
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 Site Map

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1935-469X. Print ISSN: 1554-7477
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JOP Online